Schizophyllum commune is a common basidiomycete fungus that is rarely involved in human disease. The medical records of patients operated on for fungal rhinosinusitis (FRS) in two University Hospitals between 2012 and 2014 were reviewed. Within the two-year survey, six female, and notably no male, patients were diagnosed with S. commune rhinosinusitis. Mean age was 44.6 years at diagnosis (30 to 68 years). Mean time between onset of symptoms and diagnosis was 8.5 months (2 to 12 months). All six patients were immunocompetent and had no particular host factor for FRS. S. commune was identified using MALDI-TOF mass spectrometry and identifications were confirmed via DNA sequence analysis. Chronic invasive fungal rhinosinusitis was diagnosed in three of our six patients. Based on histological findings, antifungal treatment was delivered in association with surgery. The basidiomycete fungus S. commune is an emerging cause of rhinosinusitis probably as a direct consequence of the recent technological progress in fungal identification methods (DNA sequencing and MALDI-TOF mass spectrometry).
Introduction
Schizophyllum commune (S. commune) is a common basidiomycete fungus that is rarely involved in human disease, 1 while fungal rhinosinusitis (FRS) is mostly due to Aspergillus species. Few cases of S. commune-related FRS have been reviewed in the literature. However, their number seems to be increasing since the introduction of DNA-based fungal or mass-spectrometry identification (MALDI-TOF technique) in the clinical laboratory. We report on six S. commune FRS cases diagnosed within the past two years in two tertiary care centers and reviewed the literature. Our aim is to determine whether S. commune is indeed an emerging fungal pathogen in rhinology or whether it has simply been underdiagnosed in the past.
Materials and methods
The medical records of patients operated on for a FRS in two university hospitals between June 2012 and June 2014 were reviewed. Diagnosis of FRS was assessed by histological examination showing a matted dense conglomeration of hyphae in at least one paranasal sinus, as classically reported. 27 Involvement of S. commune was assessed by mycological culture. The following preoperative data were taken into account: age, sex, nasal, neurological and ophthalmological symptoms, presence of host factors for FRS, imaging features (CT scan and MRI), inflammatory markers, histopathology, mycology, surgical and medical treatments, and clinical outcomes. Histological examination was performed using conventional Hematoxylin-Eosin-Saffron (HES), Gomori-Grocott ( Figure 1 ) and Periodic Acid-Shiff (PAS) stains.
Mycological culture
Each clinical sample was plated onto Sabouraud Gentamicin Chloramphenicol agar (OXOID, Dardilly, France) and incubated at 30
• C. The filamentous fungi were identified as soon as a fungal colony grew on the agar (usually after 48-72 hours). Species identification was assessed via their morphological, MALDI-TOF MS, and DNA sequencing features, as described below.
Morphological identification
The isolates were subjected to microscopic examination in parallel following the identification keys of the Atlas of Clinical Fungi. 28 Because S. commune usually do not sporulate under classical culture conditions and classically described nonspecific clamp connection features were not seen, morphological identification was impossible and the isolates were further identified using MALDI-TOF mass spectrometry.
MALDI-TOF mass spectrometry identification
The colonies were gently scraped with sterile plastic pliers and suspended in 75% ethanol HPLC. Next, the hydroalcoholic solution was removed via 10 min centrifugation at 13,000 g, and the pellet was suspended in 10 μl of 70% formic acid (Sigma-Aldrich, Saint-Quentin Fallavier, France) by vigorously pipetting the sample up and down. After 5-minute incubation, 10 μl of acetonitrile HPLC (VWR International S.A.S., Fontenay-sous-Bois, France) was added, and the mixture was incubated at room temperature for 5 min. Finally, the sample was centrifuged for 2 min at 13,000 g. One microliter of the supernatant (consisting of a mixture of fungal proteins) was deposited for each strain subculture in 10 replicates on a polished steel target (MTP384, Bruker Daltonics GmbH, Bremen, Germany) and air-dried. Each deposit was then covered with 1 μl of a freshly prepared solution of α-cyano-4-hydroxycinnamic acid (HCCA) in 50% acetonitrile HPLC (VWR International S.A.S., Fontenay-sous-Bois, France) and 2.5% trifluoroacetic acid HPLC (TFA) matrix (Applied Biosystems R , Villebon sur Yvette, France). Mass spectral acquisition was performed using a Microflex LT instrument (Bruker Daltonics GmbH).The spectra were acquired using the default parameters for microorganism acquisition of the RTC MaldiBiotyper software. Escherichia coli calibration was performed before every experiment using a Bruker Bacterial Test Standard (Bruker Daltonics GmbH). The obtained spectra were compared with a homemade reference spectra library, as previously described. 
Results
During the two-year survey, six female, and notably no male, patients were diagnosed with S. commune rhinosinusitis. Demographic and clinical data are shown in Table 1 . Mean age was 44.6 years at diagnosis (range 30 to 68 years). The mean time between onset of symptoms and diagnosis was 8.5 months (2 to 12 months). Sinonasal symptoms alone were observed (e.g. craniofacial pain, rhinorrhea, nasal blockage) in three cases (cases 4 to 6 in Table 1 ). In the three other cases, the same sinonasal symptoms were found but associated with ophthalmological symptoms including blurred vision, epiphora, and exophtalmia. Patients presenting with blurred vision had a normal ophthalmological examination, including visual acuity test and fundoscopic examination. All six patients were immunocompetent and had no particular host factor for FRS. A CT scan was performed on the six patients. Four of them underwent an MRI as their CT revealed bone destruction and ophthalmological symptoms (patients 1 to 4). Radiological features and biological findings are shown in Table 2 and Figures 2 and 3. Bony changes seen were true bony erosion in patients 1 to 3 and expansile remodelling in patient 4 (mucocela). Both C-reactive protein level and white cell count were normal in all patients. No biological evidence (immunoglobulin E [IgE] level and eosinophilic level) for allergic FRS was found. Patient 3 presenting with focal pachymeningitis on magnetic resonance imaging (MRI) underwent a lumbar puncture; the cerebrospinal fluid analysis results were normal.
Treatment of the six patients was surgery, either unilateral endoscopic sphenoidotomy for patients 1, 4, and 6; bilateral endoscopic sphenoidotomy for patient 3; and unilateral middle meatal antrostomy and ethmoidectomy for patients 2 and 5. Endoscopic appearance of the mucosa was normal no necrosis was seen. Removal of all the fungal contents in the sinuses was the rule. Mucosa and bone were biopsied for histological and fungal analysis in the three cases presenting with bone erosion on the preoperative images. In three patients (nos. 1 to 3), oral antifungal treatment was associated with surgery (voriconazole 800 mg/day for the first 48 hours followed by 400 mg/day) because of the mucosal and/or bone invasion. Voriconazole was administered for two months in two patients. In one patient, it had to be stopped after a month due to moderate hepatic cytolysis that fully recovered after the termination of the voriconazole treatment. Voriconazole serum levels at 1, 2, 3, and 4 weeks were respectively 3.0, 3.2, 5.6 microgram per ml, and undetectable. Bone invasion was found on histological examination in patient 3. Hyphae were found in the mucosa up to the bone in the three patients with bone destruction (patients 1 to 3) but not in the three others (4 to 6). No angioinvasion by the fungi was found. No Charcot-Leyden crystal was found. Mean follow-up was 8.6 months (2 to 24 months). Patients showed no evidence of recurrence and all were considered cured.
Discussion
Over a two-year period, we diagnosed six immunocompetent patients with FRS due to S. commune, a basidiomycete of the Agaricomycetes class, mostly found in forests as a lignicolous saprophyte. Three patients had invasive rhinosinusitis, and remarkably, no case had been diagnosed in the two study centers before 2012. Rhinosinusitis due to S. commune is rare, 22 and only 42 cases were reported in the literature from 1992 to 2014.
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Most often, authors reported isolated cases. Four types of FRS due to S. commune are reported in the literature (Table 3 acute invasive rhinosinusitis, 20, 22 and allergic fungal rhinosinusitis. 1, 5, 11, 23, 25 Chronic invasive fungal rhinosinusitis was diagnosed in three of our six patients (patients 1 to 3). In two of them, the histological analysis showed fungal hyphae up to the bone (patients 1 and 2) and actual bone invasion in patient 3. Based on histological findings, antifungal treatment was associated with surgery. According to the categorization of Chakrabarti et al., three of our six patients had chronic noninvasive FRS (patients 4 to 6). 35 Patient 4 presented with a sphenoid sinus mucocela with no preoperative suspicion of FRS. The two other patients presented with sinus fungal balls, as described in the literature. 4 21, 26 In our three patients presenting with bone erosion, there was no biological (IgE level and eosinophilic level) of allergic FRS. We report three histologically proven chronic invasive FRS due to S. commune. None of the six patients reported here had any FRS host factor or known cause of immunodeficiency. In the literature, most of the reported cases were in immunocompetent patients. 1, 4, 5, 7, 8, [10] [11] [12] [13] 16, 17, 19, 20, [24] [25] [26] What is most remarkable in our study is that we found three cases of chronic invasive rhinosinusitis, while only one case had previously been reported in the literature in immunocompetent patients. 26 Some authors suggest that the occurrence of S. commune as a human pathogenic fungus is much more frequent than previously assumed. 8 43 asthma, 44 and invasive diseases such as thoracic empyema. 45 It has also been reported as a cause of ophtalmomycoses. 46 Treatment of chronic FRS (chronic invasive FRS and fungal balls) is surgery in order to remove and identify the fungus, followed by antifungal treatment. In our patients, oral voriconazole therapy was started after the surgery. Duration of the antifungal treatment is variable in the literature. Our patients were treated for up to 2 months with oral voriconazole. In the literature, there is no consensus about antifungal treatment of chronic invasive FRS and even less consensus about S. commune FRS. Some authors used this treatment for several weeks, 8 while others did not use it at all. 13, 24 Antifungal susceptibility testing with the E-test assays failed in our nonsporulating filamentous fungi isolates. S. commune susceptibility to voriconazole has been recently reported to be active, as shown by Singh et al. 47 Regarding S. commune FRS prognosis in immunocompetent patients, like in our six patients, most of the cases reported in the literature showed a favorable outcome, and no treatment failure has been reported so far. 1, 4, 5, 7, 8, [10] [11] [12] [13] 16, 17, 19, 20, [24] [25] [26] The basidiomycete fungus S. commune is an emerging cause of rhinosinusitis. S. commune is nowadays earlier recognized due to improved diagnostics. Indeed, DNA sequencing and MALDI-TOF mass spectrometry make it possible to identify fungi whose macroscopic and microscopic morphological features are usually uninformative. 48 Yet in the GenBank database, the number of well identified nucleotide sequences of these fungi remains limited. 48 In the current context of the increasing use of MALDI-TOF mass spectrometry in microbiology laboratories, a growing number of S. commune FRS diagnoses must be expected. In keeping with results reported in the literature, our findings highlight the usually favorable outcome of S. commune invasive chronic FRS in immunocompetent patients.
